ImmuCell reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while outlining plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027. Product sales rose 11.5% year over year to $7.2 million in the second quarter of 2026, and net income increased to $1.8 million, or $0.20 per share, from $500,000, or $0.06 per share, a year earlier. Domestic sales grew 27.7% to $6.2 million, offsetting a 38.9% decline in international sales to about $1 million. The company said First Defense's share of U.S. animals treated with biological scours preventatives rose to about 19% by June from 15% in December 2025. Gross margin fell to 33.9% from 43.7% a year earlier, pressured by lower production output, scrap costs, and recurring expenses tied to the discontinued Re-Tain program.
ImmuCell CorporationDomestic demand for calf scours prevention products drove 11.5% sales growth and higher earnings.
